echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Innovative drug research and development and treatment programs to promote new breakthroughs in AIDS prevention and treatment

    Innovative drug research and development and treatment programs to promote new breakthroughs in AIDS prevention and treatment

    • Last Update: 2021-02-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    During the 3rd China International Import Expo, Wang Hui, head of the AIDS Medical Center of the Third People's Hospital of Shenzhen, and Xu Ding, head of GSK China's core prescription drugs and HIV business department, visited the People's Network for a live interview to share the current situation and innovative direction of AIDS prevention and treatment.
    the end of October 2019, 958,000 people living with HIV were reported nationwide, according to data released by the CDC, and the overall epidemic continued to be at a low epidemic level.
    most of the infected patients in China are receiving effective antiviral treatment, and the survival time of patients is also increasing.
    ," Mr Wang said.
    For AIDS two-drug therapy, Wang Hui introduced, HIV antiviral treatment has experienced many twists and turns, from the beginning only the backbone of drugs, to the back by the backbone of drugs and core drugs composed of "cocktail therapy", the current treatment program is moving towards a safer, simpler, better efficacy in the direction.
    " there are clinical options that rely on two drugs to achieve the effects of three antiviral drugs.
    advantage of this option is that patients take fewer medications and have minimal physical damage.
    " Wang Hui pointed out that the current simplified treatment in the clinical, in the real world has achieved better results, Europe and the United States and other countries have also included it in the antiviral treatment program.
    Xu Ding, GSK has been introducing new treatment programs for people living with HIV in China since 1999, and so far GSK has successfully registered eight drugs for HIV treatment with the State Drug Administration in China.
    AIDS is a major public health issue for China and the world, and the field of the disease is one of GSK's global research and development strategies.
    we are committed to continuous research and development of innovative drugs, breakthrough existing treatment options, to promote the development of AIDS prevention and treatment.
    we are also actively introducing new drugs in China to improve drug access and promote the inclusion of new treatment options in national health insurance programmes.
    " HIV virus had just been discovered and spread, because of its lethality, people were very afraid of the disease.
    in fact, in the past two decades, from the "cocktail therapy" applied to the clinical, AIDS survival rate has been effectively improved.
    Xu Ding pointed out that the diagnosis and treatment of HIV has changed a lot, patients under scientific treatment, normal life expectancy can be almost the same as normal people.
    But as the drug ages older and older, other problems inevitably arise in the body, so pay attention to the interaction between multiple drugs and try to simplify treatment options to achieve better results with fewer drugs.
    " from the simplification of the program, we put forward in China to prepare for approval of the two-drug program, previously three or four drugs, now into a double-drug has been a great progress.
    from a long-term point of view, we mainly hope to pass the needle way to achieve long-term effect.
    " Xu Ding, GSK currently has a once-a-month needle approved for sale in Canada, but also to be approved once-a-month needle treatment program.
    " GSK is developing a long-acting two-drug needle program that will allow patients to control HIV with only six injections a year in the near future.
    hope that this solution can be better and earlier to the vast number of patients in China.
    ," Mr Xu said.
    Talking about aids patients group care and AIDS prevention and control, Xu Ding said that GSK and the government, medical institutions, industry associations and other active cooperation, through various initiatives to strengthen the public awareness of AIDS, joint public welfare organizations to strengthen the care and support of AIDS patients.
    , in-depth grass-roots AIDS diagnosis and treatment training, popularize new treatment programs, improve the level of doctors at all levels.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.